TrialPath
Recruiting

A Study of Sovilnesib in Subjects With Ovarian Cancer

NCT06084416 · Volastra Therapeutics, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects With Selected Advanced Solid Tumors
About this study
This is a phase 1b study of sovilnesib in subjects with advanced solid tumors. The focus of the proposed clinical study is to establish the optimal dose of sovilnesib for further clinical development. An adaptive multi-cohort design will be used to assess the safety, tolerability, PK, and efficacy of multiple dose levels in parallel to establish the RP2D of sovilnesib. The study will be conducted in two parts: Part 1 and Part 2. Part 1 is a randomized dose optimization phase in the biomarker-unselected platinum resistant HGSOC patient population. Part 2 is a randomized dose optimization phase in the p16 positive (biomarker-selected) platinum resistant HGSOC patient population. Depending on the emerging data of the Part 1 dose optimization stage, consideration will be given to initiate sub-study cohort(s) in other selected locally advanced or metastatic tumor types to provide additional safety, PK/PD and preliminary efficacy data. Early stopping rules for safety based on a Bayesian Toxicity Monitoring Design and for futility based on a Bayesian Efficacy Monitoring via Predictive Probability Design will be applied. Sovilnesib will be given orally in 28-day cycles at selected dose levels of interest. Dosing will continue until disease progression, unacceptable toxicity, withdrawal of consent, or other stopping criteria are met.
Eligibility criteria
Key Inclusion Criteria: * All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration * Histologically confirmed locally advanced, inoperable, or metastatic tumor. * High Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer - histologically confirmed; locally advanced, inoperable or metastatic; p16 positive (Part 2 only); platinum resistant (defined as radiographic progression/recurrence \<180 days after last dose of ≥ 4 cycles of platinum containing therapy) or refractory; prior bevacizumab treatment, unless ineligible or intolerant; if germline and/or somatic BRCA1/2 mutation, previously treated with PARP-inhibitor (unless ineligible or intolerant). Key Exclusion Criteria: * Part 1 only: MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype * Endometrioid, clear cell, mucinous, sarcomatoid, low-grade/borderline ovarian tumor or mixed tumors containing any of the above histologies * Previously received KIF18A inhibitor * Leptomeningeal disease, or new or progressive CNS metastases or spinal cord compression * Cardiac parameters: MI, PE, CABG, severe/unstable angina or stroke ≤ 6 months, NYHA Class ≥ II, LVEF \< 50% * Any gastrointestinal condition (e.g. malabsorption syndrome, surgical anastomosis, short bowel syndrome) that might affect the absorption of oral medications including the study drug
Study design
Enrollment target: 150 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-04-04
Estimated completion: 2027-12
Last updated: 2026-10-13
Interventions
Drug: Sovilnesib
Primary outcomes
  • • Determination of the Recommended Phase 2 Dose (RP2D) of Sovilnesib (Up to 24 months)
  • • Frequency and duration of Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (Up to 24 months)
  • • Frequency and duration of Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0 (Up to 24 months)
Sponsor
Volastra Therapeutics, Inc. · industry
Contacts & investigators
ContactVolastra Therapeutics, Inc. · contact · clinicaltrials@volastratx.com · (646) 344-1248
All locations (11)
The University of Alabama at BirminghamRecruiting
Birmingham, Alabama, United States
University of Arkansas for Medical SciencesActive Not Recruiting
Little Rock, Arkansas, United States
Hoag Memorial HospitalActive Not Recruiting
Newport Beach, California, United States
Georgia Cancer Center Augusta UniversityRecruiting
Atlanta, Georgia, United States
Johns Hopkins HospitalActive Not Recruiting
Baltimore, Maryland, United States
Dana Farber Cancer InstituteActive Not Recruiting
Boston, Massachusetts, United States
Roswell Park Comprehensive Cancer CenterRecruiting
Buffalo, New York, United States
Icahn School of Medicine at Mount SinaiActive Not Recruiting
New York, New York, United States
OU Health Stephenson Cancer CenterRecruiting
Oklahoma City, Oklahoma, United States
MUSC Hollings Cancer CenterActive Not Recruiting
Charleston, South Carolina, United States
Fred Hutchinson Cancer CenterActive Not Recruiting
Seattle, Washington, United States
A Study of Sovilnesib in Subjects With Ovarian Cancer · TrialPath